JP2013533210A5 - - Google Patents

Download PDF

Info

Publication number
JP2013533210A5
JP2013533210A5 JP2013509186A JP2013509186A JP2013533210A5 JP 2013533210 A5 JP2013533210 A5 JP 2013533210A5 JP 2013509186 A JP2013509186 A JP 2013509186A JP 2013509186 A JP2013509186 A JP 2013509186A JP 2013533210 A5 JP2013533210 A5 JP 2013533210A5
Authority
JP
Japan
Prior art keywords
monoclonal antibody
amino acid
administration
use according
deletion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013509186A
Other languages
English (en)
Japanese (ja)
Other versions
JP6038777B2 (ja
JP2013533210A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/035033 external-priority patent/WO2011140114A2/en
Publication of JP2013533210A publication Critical patent/JP2013533210A/ja
Publication of JP2013533210A5 publication Critical patent/JP2013533210A5/ja
Application granted granted Critical
Publication of JP6038777B2 publication Critical patent/JP6038777B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013509186A 2010-05-03 2011-05-03 黄色ブドウ球菌(Staphylococcusaureus)感染のための抗グルコサミニダーゼ受動免疫化 Active JP6038777B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33056810P 2010-05-03 2010-05-03
US61/330,568 2010-05-03
PCT/US2011/035033 WO2011140114A2 (en) 2010-05-03 2011-05-03 Anti-glucosaminidase passive immunization for staphylococcus aureus infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016214728A Division JP6227092B2 (ja) 2010-05-03 2016-11-02 黄色ブドウ球菌(Staphylococcus aureus)感染のための抗グルコサミニダーゼ受動免疫化

Publications (3)

Publication Number Publication Date
JP2013533210A JP2013533210A (ja) 2013-08-22
JP2013533210A5 true JP2013533210A5 (https=) 2014-06-26
JP6038777B2 JP6038777B2 (ja) 2016-12-07

Family

ID=44904432

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013509186A Active JP6038777B2 (ja) 2010-05-03 2011-05-03 黄色ブドウ球菌(Staphylococcusaureus)感染のための抗グルコサミニダーゼ受動免疫化
JP2016214728A Active JP6227092B2 (ja) 2010-05-03 2016-11-02 黄色ブドウ球菌(Staphylococcus aureus)感染のための抗グルコサミニダーゼ受動免疫化
JP2017196867A Active JP6580649B2 (ja) 2010-05-03 2017-10-10 黄色ブドウ球菌(Staphylococcus aureus)感染のための抗グルコサミニダーゼ受動免疫化

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016214728A Active JP6227092B2 (ja) 2010-05-03 2016-11-02 黄色ブドウ球菌(Staphylococcus aureus)感染のための抗グルコサミニダーゼ受動免疫化
JP2017196867A Active JP6580649B2 (ja) 2010-05-03 2017-10-10 黄色ブドウ球菌(Staphylococcus aureus)感染のための抗グルコサミニダーゼ受動免疫化

Country Status (7)

Country Link
US (4) US9737601B2 (https=)
EP (2) EP2566891B1 (https=)
JP (3) JP6038777B2 (https=)
AU (1) AU2011248209B2 (https=)
CA (1) CA2797121C (https=)
ES (1) ES2606017T3 (https=)
WO (1) WO2011140114A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9737601B2 (en) 2010-05-03 2017-08-22 University Of Rochester Anti-glucosaminidase passive immunization for Staphylococcus aureus infections
CA2853943C (en) * 2011-11-02 2015-12-08 University Of Rochester Anti-glucosaminidase passive immunization for staphylococcus aureus infections
AU2015224393B2 (en) * 2011-11-02 2016-12-15 University Of Rochester Anti-glucosaminidase passive immunization for staphylococcus aureus infections
US9695245B2 (en) 2013-03-15 2017-07-04 Edimer Pharmaceuticals, Inc Anti-ectodysplasin antibodies
BR112016013514B1 (pt) 2013-12-13 2022-04-19 Stora Enso Oyj (Fi) Papelão de múltiplas camadas
US10759859B2 (en) 2016-01-14 2020-09-01 Bps Bioscience, Inc. Anti-PD-1 antibodies and uses thereof
EP3580241A4 (en) * 2017-02-10 2021-01-06 The Trustees Of The University Of Pennsylvania ANTIFACTOR D ANTIBODIES AND USES THEREOF
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
WO2022155421A1 (en) * 2021-01-15 2022-07-21 University Of Rochester Staphylococcus aureus antigen-based nucleic acid vaccines
JP2024507789A (ja) * 2021-02-12 2024-02-21 テーレポス バイオサイエンシーズ,エルエルシー グルコサミニダーゼと結合する抗体及びその使用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237224A (en) 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US6228619B1 (en) 1996-02-20 2001-05-08 Smithkline Beecham Corporation Glucosaminidase
WO2009137677A2 (en) * 2008-05-07 2009-11-12 Innovative Biosensors, Inc. Reagents, methods, and systems for detecting methicillin-resistant staphylococcus
EP2335073A4 (en) 2008-09-02 2012-09-26 Univ Maryland DIAGNOSIS OF BIOFILM IN VIVO INFECTION AND TREATMENT
US8318180B2 (en) * 2008-09-30 2012-11-27 University Of Maryland, Baltimore Protective vaccine against Staphylococcus aureus biofilms comprising cell wall-associated immunogens
US9737601B2 (en) 2010-05-03 2017-08-22 University Of Rochester Anti-glucosaminidase passive immunization for Staphylococcus aureus infections

Similar Documents

Publication Publication Date Title
JP2013533210A5 (https=)
Hake et al. Local antibiotic therapy strategies in orthopaedic trauma: practical tips and tricks and review of the literature
Gitelis et al. The treatment of chronic osteomyelitis with a biodegradable antibiotic-impregnated implant
Whiteside et al. One-stage revision with catheter infusion of intraarticular antibiotics successfully treats infected THA
Wolford et al. Management of the infected temporomandibular joint total joint prosthesis
Herford et al. Reconstruction of mandibular continuity defects with bone morphogenetic protein-2 (rhBMP-2)
CA2797121A1 (en) Anti-glucosaminidase passive immunization for staphylococcus aureus infections
Qiang et al. Use of antibiotic cement rod to treat intramedullary infection after nailing: preliminary study in 19 patients
Matic et al. A contraindication for the use of hydroxyapatite cement in the pediatric population
Wasko et al. Antibiotic cement nail for the treatment of posttraumatic intramedullary infections of the tibia: midterm results in 10 cases
Bhatia et al. Role of antibiotic cement coated nailing in infected nonunion of tibia
Barger et al. Antibiotic-coated interlocking intramedullary nail for the treatment of long-bone osteomyelitis
Neumann et al. Two-stage cementless revision of late total hip arthroplasty infection using a premanufactured spacer
ES3041577T3 (en) Compositions comrising an opioid growth factor receptor (ogfr) antagonist for use in promoting bone formation and in the treatment of cancer.
ES2633978T3 (es) Espaciador de articulaciones articulado de dos piezas y procedimiento para su fabricación
WO2008033221A2 (en) Therapeutic bone replacement material
Mulcahy Current approach to the treatment of penile implant infections
Shen et al. Intraoperatively-made cement-on-cement antibiotic-loaded articulating spacer for infected total knee arthroplasty
Katanec et al. Use of recombinant human bone morphogenetic protein (rhBMP2) in bilateral alveolar ridge augmentation: case report
Ebied et al. A protocol for staged arthroplasty to salvage infected nonunion of hip fractures
Mulcahy Penile implant infections: prevention and treatment
Jokhio et al. Antibiotic Cement Coated Nailing in Infected Nonunion of Tibia
Casap et al. Imperforate titanium shell enclosing recombinant human bone morphogenetic protein-2–induced bone formation for high-profile dental implants in rabbit tibia
WO2025106896A1 (en) Coating of medical and implant biomaterials with an anti-biofilm agent to prevent and treat infection
Deshmukh et al. Treatment of Infected Tibia Non-union Using a Novel Solid Intramedullary Nail Custom-Made for Antibiotic-Impregnated Cement Coating.